Clinical Trial Update: A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing patient preference between ODM-201 (darolutamide) and enzalutamide in men with metastatic castration-resistant prostate cancer has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)
• ODM-201 (darolutamide)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Metastatic Castrate-resistant Prostate (CRPC) Cancer | Phase 2 | Status: COMPLETED